Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.
Issue link: http://todaysveterinarypractice.epubxp.com/i/919967
57 JANUARY/FEBRUARY 2018 ● TVPJOURNAL.COM CONTINUING EDUCATION 7. Favrot C, Steffan J, Seewald W, et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010;21:23-30. 8. Fontaine J, Heimann M, Day MJ. Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. Vet Dermatol 2010;21:267-275. 9. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006;114:2007-2008. 10. Sousa CA, Halliwell REW. The ACVD task force on canine atopic dermatitis (XI): the relationship between arthropod hypersensitivity and atopic dermatitis in the dog. Vet Immunol Immunopathol 2001;81:233-238. 11. Borio S, Colombo S, La Rosa G, et al. Effectiveness of a combined (4% chlorhexidine digluconate shampoo and solution) protocol in MRS and non-MRS canine superficial pyoderma: a randomized, blinded, antibiotic-controlled study. Vet Dermatol 2015;26:339-344. 12. Hillier A, Lloyd DH, Weese JS, et al Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol. 2014;25:163-175. 13. Papich MG. Incompatible critical care drug combinations. In Bonagura JD (ed): Kirk's Current Veterinary Therapy XII. Philadelphia: WB Saunders, 1995:194-198. 14. Jackson HA, Murphy KM, Tater KC, et al. The pattern of allergen hypersensitivity (dietary or environmental) of dogs with non-seasonal atopic dermatitis cannot be differentiated on the basis of historical or clinical information: a prospective evaluation 2003-2004. Vet Dermatol 2005;16:200. 15. Gaschen FP, Merchant SR. Adverse food reactions in dogs and cats. Vet Clin North Am Small Anim Pract 2011;41:361-379. 16. Bexley J, Nuttall TJ, Hammerberg B, et al. Co-sensitization and cross- reactivity between related and unrelated food allergens in dogs—a serological study. Vet Dermatol 2017;28:31-e7. 17. Bizikova P, Olivry T. A randomized, double-blinded crossover trial testing the benefit of two hydrolysed poultry-based commercial diets for dogs with spontaneous pruritic chicken allergy. Vet Dermatol 2016;27:289-e70. 18. Raditic DM, Remillard RL, Tater KC. ELISA testing for common food antigens in four dry dog foods used in dietary elimination trials. J Anim Physiol Anim Nutr (Berl) 2011;95:90-97. 19. Olivry T, Mueller RS, Prélaud P. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res 2015;11:225. 20. S winnen C, Vroom M. The clinical effect of environmental control of house dust mites in 60 house dust mite-sensitive dogs. Vet Dermatol 2004;15:31-36. 21. Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol 2017 Sep 20. 22. Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2. Vet Derma tol 2017;28:183-e40. 23. Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Derma tol 2017 Aug 4. 24. Canonica G, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:3-5 2. 25. Marsella R. Tolerability and clinical efficacy of oral immunotherapy with house dust mites in a model of canine atopic dermatitis: a pilot study. Vet Dermatol 2010;21:566-571. 26. Marsella R, Ahrens K. Investigations on the effects of sublingual immunotherapy on clinical signs and immunological parameters using a canine model of atopic dermatitis: a double-blinded, randomized, controlled study (abstract). Vet Dermatol 2012;23:66. 27. DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol 2016;27:82-7e23 28. Plant JD, Neradelik MB, Polissar NL, et al. Agreement between allergen- specific IgE assays and ensuing immunotherapy recommendations from four commercial laboratories in the USA. Vet Dermatol 2014;25:15-e6. 29. Ihrke PJ, Norton AL, Ling GV, et al. Urinary tract infection associated with long-term corticosteroid administration in dogs with chronic skin diseases. J AVMA 1985;186:43-46. 30. Torres SM, Diaz SF, Nogueira SA, et al. Frequency of urinary tract infection among dogs with pruritic disorders receiving longterm glucocorticoid treatment. JAVMA 2005;227:239-243. 31. Gross TL, Walder EJ, Ihrke PJ. Subepidermal bullous dermatosis due to topical corticosteroid therapy in dogs. Vet Dermatol 1997;8:127-131. 32. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742-750. 33. Nuttall T, Mueller R, Bensignor E, et al. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol 2009;20:191-198. 34. L ourenço AM, Schmidt V, São Braz B, et al. Efficacy of proactive long- term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double-blind placebo controlled pilot study. Vet Dermatol 2016;27:88-92. 35. Rème CA, Dufour P. Effects of repeated topical application of a 0.0584% hydrocortisone aceponate spray on skin thickness in beagle dogs. Intern J Appl Res Vet Med 2009;8:221-226. 36. Paradis M, Scott DW, Giroux D. Further investigations on the use of nonsteroidal and steroidal antiinflammatory agents in the management of canine pruritus. JAAHA 1991;27:44-48. 37. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015;26:171-179. 38. Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem 2013;52:153-223. 39. US Food and Drug Administration. Apoquel. Oclacitinib Tablet. Freedom of information summary. Original new drug application. NADA 141-345. fda.gov/downloads/AnimalV.../UCM363901.pdf Accessed November 13, 2017. 40. Banovic F, Gordon H, Tarigo J, et al. Modulatory effects of oclacitinib on in vitro canine T-cell proliferation and cytokine production (abstract). Vet Dermatol 2017. doi: 10.1111/vde.12468. 41. Simpson AC, Schissler JR, Rosychuk RAW. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Vet Dermatol 2017;28:485-e113. 42. Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec 2014;174:3-12. Frane Banovic Frane Banovic, DVM, PhD, DECVD, is an assistant professor of dermatology at the University of Georgia College of Veterinary Medicine. After graduating from veterinary school in Zagreb (Croatia) in 2008, Dr. Banovic continued with further education at the University of Zagreb by pursuing a PhD program in veterinary microbiology. In the summer of 2011, Dr. Banovic finished a 1-year rotational internship at the Veterinary School in Munich, Germany, and started his 3-year dermatology residency program at the North Carolina State University College of Veterinary Medicine. After finishing residency, he enrolled in a postdoctoral fellowship in investigative dermatology, with a primary research focus of skin antiseptics and pathogenesis of cutaneous staphylococcal infections. He is board-certified by the European College of Veterinary Dermatology. Dr. Banovic's main research interests lie in the field of canine atopic dermatitis, related staphylococcal skin infections, and autoimmune skin diseases.